We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BOSTON SCIENTIFIC OBTAINS EXCLUSIVE PACLITAXEL LICENSE
BOSTON SCIENTIFIC OBTAINS EXCLUSIVE PACLITAXEL LICENSE
December 3, 2004
Boston Scientific recently exercised its right under an existing agreement to obtain an exclusive license for the use of paclitaxel, the active agent used in the company’s Taxus Express2 coronary stent system.